An immunotherapeutic assay in SOD1G93A slow ALS mice model was performed.

As antigen for vaccination, a SOD1 peptide was used.

Immunotherapy does not result in an improved clinical or pathological outcome.

Vaccinated animals showed increased neuroinflammation in the spinal cord.

Vaccine induced an adverse response that counteracts its possible beneficial effect.